Opendata, web and dolomites


Biomechancial Aneurysm Risk Assessment Trial

Total Cost €


EC-Contrib. €






Project "BARAT" data sheet

The following table provides information about the project.


Organization address
city: GRAZ
postcode: 8010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website and http
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-03-01   to  2015-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VASCOPS GMBH AT (GRAZ) coordinator 50˙000.00


 Project objective

The formation of aortic aneurysms is the by far the most common aortic disease and its prevalence (1%-5% in the 65 population) strongly increases with age. Expensive aneurysm repair interventions (about 60k per year in Europe) are performed in order to prevent aortic aneurysms from rupture. However, oversimplified criteria like the maximum transverse aortic diameter or the aortic expansion rate are used to indicate aneurysm repair. These criteria fail to provide patient-specific (individualized) treatment indication, such that many patients are treated without a reason and health care resources are wasted. In contrast VASCOPS’ A4clinics software allows a detailed biomechanical rupture risk assessment, and hence, allows prioritizing patients according to their individual risk of aortic rupture. The market volume for such diagnostic information is estimated to 12000k€ per year in Europe. A4clinics is patented, CE approved and achieved already Technology Readiness Level 9. Despite first retrospective validation studies demonstrated the clinical benefit of the system large prospective validation is needed to fully convince clinicians and to commercially exploit the product. Consequently, the aim of this proposal is to develop a clinical validation plan for the A4clinics software, which is tightly linked to its successful large-scale commercialization. Key points are the definition of a targeted validation strategy and the installation of an effective network of clinical partners, who also should serve as national contact points for product commercialization. In addition early measures to gain awareness of the validation initiative and links to product distribution plans are investigated. The planning will be performed in collaboration with our clinical contact at Karolinska University Hospital in Stockholm, Sweden. Stockholm area screens for aneurysm patients, and, as such provides latest, and for most European countries, a future health care environment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BARAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BARAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More